NewsEurope20,000 German Pharmacies To Stock Canadian Firm’s Cannabis

20,000 German Pharmacies To Stock Canadian Firm’s Cannabis

-

THE first European deal for Canadian firm MediPharm Labs will see its medical cannabis products made available to 20,000 German pharmacies.

With dual listings on the Ontario and Frankfurt stock exchanges MediPharm says this new deal is an important milestone in its global ambitions.

And, it follows hot on the heels of its first ever international agreement in the Australian market, earlier this year.

In a stock market statement MediPharm highlights why it has targeted Germany as its first European port of call.

It says the German medical cannabis market currently serves up to 50,000 patients; a very rapid advance since legalisation in March 2017. With a population of over 80 million it is set to be Europe’s largest medical cannabis. 

MediPharm’s ‘white label’ agreement with Germany pharmacy ADREXpharma will see its supply ‘high quality, purity assured, cannabis concentrate derivative products, including THC and CBD oil, for sale and distribution under the ADREXpharma brand’, it says in the market release. 

ADREXpharma is licensed wholesale distributor of controlled drugs and medical cannabis, saying it serves almost all of Germany’s 20,000 pharmacies. 

Mario Eimuth, Chief Executive Officer, at ADREXpharma, said MediPharm shares its ‘patient-centric focus’ and is its ‘ideal partner’.

Founded in 2015, MediPharm specializes in the production of purified, pharmaceutical-grade cannabis oil and concentrates, utilizing Good Manufacturing Practices. 

It has five primary extraction lines with an annual capacity of 300,000 kg of  dried cannabis with complementary wholesale and white labelling capabilities.

MediPharm is set to shortly complete construction of a new extraction facility in Wonthaggi, Victoria, which will feature supercritical carbon dioxide extraction.

This will  be able to process up to 75,000 kg of dried cannabis annually, as well as incorporating secondary processing equipment for the manufacture of purified and high-concentrate cannabis distillate. 

It has agreed terms, initially for one year, with an Australian Licensed Producer to source dried flower for the facility.

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Germany’s ‘KanaVape’ Moment As Police And Courts Crackdown On ‘Narcotic’ Hemp & CBD

TWO senior figures in the European cannabis industry are leading the fight against over-zealous German law enforcement in a...

UK CBD Consumption To Switch From Oils To Capsules – As New Research Estimates Market Value At £690m

CAPSULES are set to replace oils as the preferred method of CBD consumption - as new research show the...

Crowdfunding: An Emerging Capital Greenhouse For The Cannabis Industry

ALPHAGREEN is expected to hit close to the £2m crowdfunding mark on the Seedrs platform by mid-May – double...

Former JP Morgan Banker Lands Two UK Cannabis Jobs

A VETRAN of American investment bank JP Morgan has entered the burgeoning field of cannabis with appointments to two...

Europe’s Hemp Pioneer Posts Record Results With CBD, Construction And Car-Making To The Fore

EUROPEAN pioneer HempFlax has posted record annual results with revenues up 43% to €14.5m (£12.5m) as it returned a...

Sales Up Sharply At Sativa Wellness But Operational Costs Lead to £4.5m Loss

BRITISH CBD firm Sativa Wellness saw annual sales rise by over one-third in an eventful year which saw it...

Must read

Germany’s ‘KanaVape’ Moment As Police And Courts Crackdown On ‘Narcotic’ Hemp & CBD

TWO senior figures in the European cannabis industry are...

You might also likeRELATED
Recommended to you